Dental bone grafting supports more than half of dental implant procedures, and a small group of companies supplies most of the materials behind it.
iData Research values the global dental bone graft substitute and other biomaterials market at $2.33 billion in 2025, growing at a 7.2% CAGR.
This guide ranks the top dental bone graft companies in 2026 and explains what keeps each one ahead.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top dental bone graft companies in 2026
➜ Why Geistlich Pharma leads the dental bone graft market
➜ What makes Henry Schein a top dental bone graft company
➜ Why ZimVie ranks among the top dental bone graft companies
➜ How big is the dental bone graft and biomaterials market
➜ Dental bone graft companies frequently asked questions
Key Takeaways
- The top three dental bone graft companies in 2026 are Geistlich Pharma, Henry Schein, and ZimVie, ranked by iData Research market share.
- Geistlich Pharma holds the number one position in both the dental bone graft substitute and dental barrier membrane segments.
- The global dental bone graft substitute and other biomaterials market reached $2.33 billion in 2025 and is forecast to near $3.8 billion.
- Market growth is closely tied to rising dental implant procedures, since grafting prepares the site for many implants.
Who are the top dental bone graft companies in 2026?
The top three dental bone graft companies in 2026 are Geistlich Pharma, Henry Schein, and ZimVie, ranked by market share in iData Research data.
Together they lead the global dental bone graft substitute and other biomaterials market, valued at $2.33 billion in 2025.
Geistlich Pharma sits at the top, holding significant shares across both the dental bone graft substitute and dental barrier membrane segments.
Henry Schein ranks second in the dental bone graft substitute segment, driven by its BioHorizons and ACE Southern specialty brands.
ZimVie holds the third position in the dental bone graft substitute segment and competes closely across allografts, xenografts, synthetics, and membranes.
All three dental bone graft companies compete with broad regenerative portfolios that span multiple material types and grafting indications.
Why Geistlich Pharma leads the dental bone graft market
Geistlich Pharma remains the leading competitor in the global dental bone graft substitute and dental biomaterials market.
The company holds the number one position in both the dental bone graft substitute and dental barrier membrane segments.
Its focus on bone and soft-tissue regeneration gives it a strong position in regenerative dentistry.
The Bio-Oss bovine xenograft and Bio-Gide collagen membrane are widely used in guided bone regeneration procedures.
Geistlich has strengthened its position through recent moves, including the 2024 acquisition of Bionnovation Biomedical and a 2025 investment in ReOss for patient-specific regenerative solutions.
In October 2025, the company launched Bio-Gide Forte in North America, with its European launch in preparation.
Across 2026, Geistlich has announced plans to launch 20 new regenerative products in more than 40 countries, along with a flowable version of Bio-Oss.
Despite growing competition from lower-priced regional products, Geistlich is expected to keep a strong presence over the forecast period.
What makes Henry Schein a top dental bone graft company
Henry Schein strengthened its position as the second-largest global competitor in the dental bone graft substitute market in 2025.
Its performance is driven mainly by its specialty brands, most notably BioHorizons and ACE Southern.
BioHorizons serves as the cornerstone of the company’s regenerative and implant-related portfolio.
Its dental bone graft substitute lineup includes MinerOss, Grafton DBM, and LADDEC, which support a broad range of grafting indications.
The MinerOss platform offers cortical, cancellous, and composite allograft options.
ACE Southern extends Henry Schein’s reach through a strong presence in surgical and grafting consumables, reinforcing distribution depth and brand visibility.
Together, these subsidiary brands have been central to Henry Schein’s competitive positioning and sustained growth in the market.
Why ZimVie ranks among the top dental bone graft companies
ZimVie remained a leading competitor in the global dental bone graft substitute and dental biomaterials market in 2025.
The company competes with a broad regenerative portfolio spanning allografts, xenografts, synthetic grafts, and barrier membranes.
Its Puros Allograft, RegenerOss, and Endobon product lines compete directly with offerings from Geistlich Pharma and BioHorizons.
In 2025, ZimVie was acquired by the private equity firm ARCHIMED, moving from a publicly traded entity to a privately held company.
The acquisition completed in October 2025, and ZimVie continues to operate as an independent company under its own brand.
iData Research expects this change to support further investment in ZimVie’s dental implant and regenerative biomaterials portfolio.
How big is the dental bone graft and biomaterials market?
The global dental bone graft substitute and other biomaterials market was valued at $2.33 billion in 2025, according to iData Research.
The market is expected to grow at a 7.2% CAGR to reach nearly $3.8 billion over the forecast period.
This market includes dental bone graft substitutes, dental barrier membranes, local antimicrobial periodontal treatments, and dental soft tissue wound care.
Growth is closely tied to the dental implant market, since a large share of implant procedures require bone grafting to address insufficient bone volume.
Rising implant adoption is driven by aging populations, higher rates of tooth loss, and expanding access to care, as covered in our guide to the top dental implant companies.
Asia-Pacific now holds the largest share of the global dental bone graft substitute market.
The main limiter is the high cost of procedures, which continues to restrict patient access where reimbursement is inconsistent.
Dental bone graft companies frequently asked questions
Who is the largest dental bone graft company in 2026?
Geistlich Pharma is the largest dental bone graft company in 2026, holding the number one position in both the dental bone graft substitute and dental barrier membrane segments.
What is the dental bone graft and biomaterials market worth?
iData Research values the global market at $2.33 billion in 2025, with growth at a 7.2% CAGR toward nearly $3.8 billion.
What products do dental bone graft companies make?
They make xenografts such as Bio-Oss, allografts such as MinerOss and Puros, synthetic grafts, and barrier membranes such as Bio-Gide.
Is ZimVie still a public company?
No, ZimVie was acquired by the private equity firm ARCHIMED in 2025 and now operates as a privately held company.
Why is the dental bone graft market growing?
Growth is tied to rising dental implant procedures, since bone grafting prepares the implant site in many cases, supported by clinical research on guided bone regeneration.
For full competitive market share data, segmentation, and forecasts, see the iData Research global dental bone graft substitute and other biomaterials market report.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
